Will stereotactic radiation prior to immunotherapy lead to better results for metastatic lung cancer?

Patients with metastatic lung cancer can participate in a trial at the Netherlands Cancer Institute looking into whether stereotactic radiation prior to immunotherapy treatment will provide better results than immunotherapy alone. Immunotherapy currently proves effective for 20 to 30 percent of patients with metastatic lung cancer. Stereotactic radiation treatment may expand this percentage. The trial, PembroRT, tries to find out why some patients can benefit from immunotherapy while others do not.